Healthcare shares were flat to higher in pre-market trade on
In healthcare stocks news, OncoGenex Pharmaceuticals, Inc. (
) shares plunged more than 48% pre-market after the company said
results from its Phase 3 SYNERGY trial to add custirsen to standard
first-line treatment of docetaxel/prednisone in men with metastatic
prostate cancer failed to meet primary endpoints.
The stock which was halted from trading ahead of the news,
recently changed hands at $5.00, off an earlier low of $4.25. The
shares haven't been at this level in regular trading since
And, Haemonetics Corporation (
) reported financial results for Q4, or the quarter ended March 29,
2014, that fell short of analysts' expectations, and provided
guidance for fiscal 2015 and 2016.
The healthcare company engaged in providing blood management
solutions reported Q4 net income of $10.2 million or $0.19 per
share, compared with $12.56 million or $0.24 per share in the
Finally, Techne Corporation (
) reported financial results for Q3, or the quarter ended March 31,
2014, that topped analysts' expectations, and declared a quarterly
The developer and manufacturer of biotechnology products and
hematology calibrators and controls reported Q1 $31.6 million or
$0.85 per diluted share, compared with $33.12 million or $0.90 per
share in the prior-year period.
Adjusted earnings for the quarter were $34.7 million or $0.94
per diluted share, compared with $32.46 million or $0.88 per share
in the same period the prior year. The Capital IQ analyst estimate
is for $0.89 EPS.
Copyright (C) 2014 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.